Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Trading banner 1
Trading banner 2
Trading banner 3
Trading banner 4
Trading banner 5
Trading banner 6
Trading banner 7
Trading banner 8
Trading banner 9
Asset icon - trade crypto, stocks, and gold on Pluang

Buy & Sell Adaptive Biotechnologies Corp (ADPT) – Adaptive Biotechnologies Corp Price Today

24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

ADPT trades at $14.47, up 2.77% today. The stock shows a neutral technical signal with mixed moving averages and oscillators. Fundamentally, the company is in a growth phase with revenue projected to rise to $277M in 2025, though it remains unprofitable with a net margin of -21.48%. Recent quarters have seen earnings beats, and analyst sentiment is positive with a consensus price target of $21.33. However, significant insider selling by executives, including the CEO and COO, has occurred in recent months.
The outlook for ADPT hinges on its ability to sustain revenue growth and achieve profitability. The high buy rating from analysts suggests potential upside, but persistent losses and insider selling pose risks. Investors should weigh the growth trajectory against the current lack of earnings and cautious insider activity.
Read full analysis

Key Stats

  • Market Cap
    $2.23B
  • Sector
    Health
  • 3M Drawdown
    -35.47%
  • Enterprise Value
    $2.08B
  • Dividend Yield
    -
  • Typical Hold Time
    32 days
$14.47
52W Low: $6.83
21 Apr 2025
52W High: $20.46
24 Nov 2025

Adaptive Biotechnologies Corp (ADPT) is currently valued at a market capitalization of $2.23B, with an enterprise value of $2.08B. Over the past 52 weeks, Adaptive Biotechnologies Corp has traded between a low of $6.83 and a high of $20.46, highlighting its annual price range. Over the past three months, Adaptive Biotechnologies Corp has recorded a drawdown of -35.47%, reflecting recent price volatility. On average, investors hold Adaptive Biotechnologies Corp for approximately 32 days, indicating typical investor behavior on the platform.

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.


Technical Indicators
|
|
|
Overall Summary
Bearish (19)Neutral (2)Bullish (6)

People also bought


US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions

Key Stats

  • Market Cap
    $2.23B
  • Sector
    Health
  • 3M Drawdown
    -35.47%
  • Enterprise Value
    $2.08B
  • Dividend Yield
    -
  • Typical Hold Time
    32 days
$14.47
52W Low: $6.83
21 Apr 2025
52W High: $20.46
24 Nov 2025

Adaptive Biotechnologies Corp (ADPT) is currently valued at a market capitalization of $2.23B, with an enterprise value of $2.08B. Over the past 52 weeks, Adaptive Biotechnologies Corp has traded between a low of $6.83 and a high of $20.46, highlighting its annual price range. Over the past three months, Adaptive Biotechnologies Corp has recorded a drawdown of -35.47%, reflecting recent price volatility. On average, investors hold Adaptive Biotechnologies Corp for approximately 32 days, indicating typical investor behavior on the platform.

Let’s invest in this asset by signing up or download!